[go: up one dir, main page]

LT2547205T - Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai - Google Patents

Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai

Info

Publication number
LT2547205T
LT2547205T LTEPPCT/US2011/029283T LTUS2011029283T LT2547205T LT 2547205 T LT2547205 T LT 2547205T LT US2011029283 T LTUS2011029283 T LT US2011029283T LT 2547205 T LT2547205 T LT 2547205T
Authority
LT
Lithuania
Prior art keywords
stem cells
cancer stem
novel methods
targeting cancer
targeting
Prior art date
Application number
LTEPPCT/US2011/029283T
Other languages
English (en)
Inventor
Chiang Li
David Leggett
Youzhi Li
Wei Li
Original Assignee
1Globe Biomedical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co., Ltd. filed Critical 1Globe Biomedical Co., Ltd.
Publication of LT2547205T publication Critical patent/LT2547205T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEPPCT/US2011/029283T 2010-03-19 2011-03-21 Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai LT2547205T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31589010P 2010-03-19 2010-03-19
US31588610P 2010-03-19 2010-03-19
US32581410P 2010-04-19 2010-04-19
PCT/US2011/029283 WO2011116399A1 (en) 2010-03-19 2011-03-21 Novel methods for targeting cancer stem cells

Publications (1)

Publication Number Publication Date
LT2547205T true LT2547205T (lt) 2024-06-10

Family

ID=47678420

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2011/029283T LT2547205T (lt) 2010-03-19 2011-03-21 Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai

Country Status (18)

Country Link
US (2) US9730909B2 (lt)
EP (1) EP2547205B1 (lt)
JP (1) JP2013522326A (lt)
CN (1) CN103025159A (lt)
AU (1) AU2011227023B2 (lt)
BR (1) BR112012023660B8 (lt)
CA (2) CA2793527A1 (lt)
DK (1) DK2547205T3 (lt)
ES (1) ES2987670T3 (lt)
FI (1) FI2547205T3 (lt)
HR (1) HRP20240658T1 (lt)
LT (1) LT2547205T (lt)
PL (1) PL2547205T3 (lt)
RS (1) RS65536B1 (lt)
RU (1) RU2591823C2 (lt)
SI (1) SI2547205T1 (lt)
SM (1) SMT202400193T1 (lt)
WO (1) WO2011116399A1 (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5701603B2 (ja) 2007-09-10 2015-04-15 ボストン バイオメディカル, インコーポレイテッド Stat3経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
NZ712826A (en) * 2010-03-19 2017-03-31 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
WO2014169078A2 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
JP6695275B2 (ja) 2014-02-07 2020-05-20 ボストン バイオメディカル, インコーポレイテッド 3−置換カルボニル−ナフト[2,3−b]フラン誘導体又はその薬学的に許容される塩
WO2015190489A1 (ja) 2014-06-09 2015-12-17 京都薬品工業株式会社 新規抗癌剤
KR20180006919A (ko) 2015-04-17 2018-01-19 보스톤 바이오메디칼, 인크. 암의 치료 방법
TW201713327A (zh) 2015-04-17 2017-04-16 波士頓生醫公司 治療癌症之方法
CA2988126A1 (en) * 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
JP2019506392A (ja) 2016-01-20 2019-03-07 ボストン バイオメディカル, インコーポレイテッド がんを処置するための方法
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
SG11202008686TA (en) * 2018-03-08 2020-10-29 Exxonmobil Res & Eng Co Spirocentric compounds and polymers thereof
BR112021006898A2 (pt) 2018-10-12 2021-07-20 1Globe Biomedical Co., Ltd. nova solução de combinação para tratar câncer refratário à quimioterapia
CN111825644B (zh) * 2019-04-18 2023-07-28 中国医学科学院药物研究所 2,3-二氢萘并[2,3-b]呋喃-4,9-二酮类化合物及其制备方法和用途
CN117350965A (zh) * 2023-10-07 2024-01-05 中国原子能科学研究院 对象内放射性微球的指标预估装置

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
EP1146869A2 (en) 1999-01-27 2001-10-24 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
DK1206436T3 (da) 1999-08-02 2005-02-14 Hoffmann La Roche Retinoider til behandling af emfysem
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US7998947B2 (en) 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
AU2002357012A1 (en) 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US20030139466A1 (en) * 2001-11-29 2003-07-24 Peritt David L. Methods for pretreating a subject with extracorporeal photopheresis
CN1652813A (zh) 2002-03-15 2005-08-10 纳蒂芒公司 包含甘露糖结合凝集素的药用组合物
WO2004026253A2 (en) * 2002-09-17 2004-04-01 Arqule, Inc. Novel lapacho compounds and methods of use thereof
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
BRPI0416981A (pt) 2003-12-11 2007-02-21 Univ Texas compostos para tratamento de doenças proliferativas de célula
WO2005110477A2 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Jak 저해제들과 bcr-abl, flt-3, fak 또는raf 키나제 저해제들 중 하나 이상의 조합물
CN101511179A (zh) 2005-02-25 2009-08-19 密执安州立大学董事会 Stat3的小分子抑制剂及其用途
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101142202A (zh) * 2005-03-16 2008-03-12 太日保日本株式会社 抗癌化合物及其中间体和生产方法
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2007100640A2 (en) 2006-02-21 2007-09-07 The Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
JP5654233B2 (ja) 2006-03-31 2015-01-14 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 経口で生物学的に利用できるコーヒー酸関連抗癌剤
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性2−(1−ヒドロキシエチル)−5−ヒドロキシナフト[2,3−b]フラン−4,9−ジオンの製法
JP5701603B2 (ja) 2007-09-10 2015-04-15 ボストン バイオメディカル, インコーポレイテッド Stat3経路阻害剤および癌幹細胞経路阻害剤の新規のグループ
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
NZ712826A (en) * 2010-03-19 2017-03-31 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells

Also Published As

Publication number Publication date
US20170319537A1 (en) 2017-11-09
US9730909B2 (en) 2017-08-15
EP2547205A1 (en) 2013-01-23
BR112012023660B8 (pt) 2021-05-25
CN103025159A (zh) 2013-04-03
AU2011227023A1 (en) 2012-09-27
CA2793527A1 (en) 2011-09-22
EP2547205A4 (en) 2013-08-14
US20130028944A1 (en) 2013-01-31
RU2012144420A (ru) 2014-04-27
HRP20240658T1 (hr) 2024-08-16
RU2591823C2 (ru) 2016-07-20
JP2013522326A (ja) 2013-06-13
SI2547205T1 (sl) 2024-08-30
DK2547205T3 (da) 2024-05-27
BR112012023660A2 (pt) 2015-09-15
WO2011116399A1 (en) 2011-09-22
CA2946890A1 (en) 2011-09-22
ES2987670T3 (es) 2024-11-15
SMT202400193T1 (it) 2024-07-09
AU2011227023B2 (en) 2015-05-28
FI2547205T3 (fi) 2024-05-27
PL2547205T3 (pl) 2024-07-08
EP2547205B1 (en) 2024-03-20
RS65536B1 (sr) 2024-06-28
BR112012023660B1 (pt) 2021-05-18

Similar Documents

Publication Publication Date Title
LT2547205T (lt) Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai
EP2547334A4 (en) NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS
IL220756A0 (en) Herbicide-tolerant plants
EP2749641A4 (en) CANCER STEM CELLS ISOLATION
HK1201556A1 (en) Enhanced stem cell composition
HUE066482T2 (hu) Új eljárások rákõssejtek megcélzására
EP2601290A4 (en) SOMATIC STEM CELLS
EP2772268B8 (en) Cancer stem cell-specific molecule
GB201016139D0 (en) Cancer phosholipidome
HUE038864T2 (hu) Herbicid-toleráns növények
IL255309A0 (en) Reprogramming of cancer cells
EP2760996A4 (en) SOMATIC STEM CELLS
WO2011116344A9 (en) Targeting cancer stem cells
GB201012590D0 (en) Methods for diagnosing cancer
PT2831110T (pt) Terapia anti-emp2 reduz as células-tronco do cancro
PL3536334T3 (pl) Szczepionki przeciw rakowi ukierunkowane na komórki macierzyste raka
WO2012106368A9 (en) Methods for inhibiting prostate cancer
SG196714A1 (en) Cancer stem cell inhibition
GB201021372D0 (en) CD24 cancer stem cell
ZA201205860B (en) Herbicide-tolerant plants
AU2011900981A0 (en) Inhibition of cancer stem cells
GB201012495D0 (en) Targeted differntiation of stem cells
HUE044196T2 (hu) Sejtterápia
EP2598166A4 (en) CELLS WITHOUT CMH
GB201019304D0 (en) Cells